Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX(TM), a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

About this update from Vortex Energy Corp.

[{"type":"text","content":"Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n Vertex Pharmaceuticals Incorporated\n \n (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology.\n \n\n “We are honored to be recognized at Premier’s 2025 Innovation Celebration. This reflects our unwavering commitment to bringing innovative medicines, like JOURNAVX — a non-opioid and the first new class of pain medicine approved in decades — to patients with significant unmet need,” said Duncan McKechnie, Executive Vice President and Chief Commercial Officer at Vertex.\n \n\n “Premier proudly acknowledges Vertex’s outstanding commitment to advancing health care,” said Bruce Radcliff, Senior Vice President, Supply Chain, at Premier. “Their innovative product, recognized at our 2025 Innovation Celebration, reflects our shared mission to drive cost-efficiency, operational excellence and improved patient outcomes. We applaud Vertex for their invaluable contributions to health care.”\n \n\n Premier’s Innovation Celebration is entering its 14th year of recognizing and honoring supplier product innovations. With roughly 120 nominations this year, member clinicians, physicians and supply chain experts rigorously evaluate these technologies and services for their merit. Vertex will be formally recognized on July 15, 2025, at Premier’s annual Breakthroughs Conference and Exhibition.\n \n\n\n About JOURNAVX™ (suzetrigine)\n \n\n JOURNAVX (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral pain-sensing neurons (nociceptors), where its role is to transmit pain signals (action potent...

More updates from Vortex Energy Corp.